ICAM1 and cancer: With the addition of ICAM-1 ligand LFA1-P, we were able to direct GT DcNPs to 4T1 MBC cells in lung tissues to further increase drug accumulation in cancer cells and reduce the toxicity caused by off-target effects [8,9].